European Regulator Approves Two Corona Treatments
The European Medicines Agency (EMA) recommends that the European Commission approve two antibody-based treatments against COVID-19. The EMA announced this on Thursday.
It concerns the antibody cocktail Ronapreve from the Swiss pharmaceutical company Roche and Regkirona from the South Korean Celltrion Healthcare.
Ronapreve (casirivimab/imdevimab) is intended to treat COVID-19 in adults and children over 12 years of age who do not require supplemental oxygen but are at risk of becoming seriously ill. The treatment can also have a preventive effect against COVID-19. Ronapreve is given intravenously, by infusion or injection.
The treatment has already been approved through an emergency procedure in several other countries, including the United Kingdom and the United States. Former US President Donald Trump received the treatment last year after he became infected with the coronavirus when the antibody cocktail had not yet been officially approved in the US.
Regkirona (regdanvimab) is recommended by the EMA in adults who do not need extra oxygen but risk becoming seriously ill.
They are the first treatments with COVID-19 antibody cocktails to be recommended for approval by the EMA. However, the European Commission has yet to confirm the approval.
Until now, only the medicine Veklury (remdesivir) has been approved as a special corona medicine in the EU. The American Gilead Sciences developed it.